The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 3 , Pages 703-709 , March 2009

A new strategy for prevention of anastomotic stricture using tacrolimus-eluting biodegradable nanofiber

  • Masato Mutsuga, MD

      Affiliations

    • Nagoya University, Graduate School of Medicine, Department of Cardiothoracic Surgery, Nagoya, Aichi, Japan
    • ,
  • Yuji Narita, MD, PhD

      Affiliations

    • Nagoya University, Graduate School of Medicine, Department of Cardiothoracic Surgery, Nagoya, Aichi, Japan
    • Department of Clinical Cell Therapy and Tissue Engineering, Nagoya University School of Medicine, Nagoya, Aichi, Japan
    • Corresponding Author InformationAddress for reprints: Yuji Narita, MD, PhD, Department of Clinical Cell Therapy and Tissue Engineering, Nagoya University School of Medicine, 65 Tsurumaicho, Syowa-ku, Nagoya, Aichi 466-8550, Japan.
    • ,
  • Aika Yamawaki, BMedEng

      Affiliations

    • Department of Clinical Cell Therapy and Tissue Engineering, Nagoya University School of Medicine, Nagoya, Aichi, Japan
    • ,
  • Makoto Satake, PhD

      Affiliations

    • Department of Tissue Engineering Development, Teijin Technology Innovation Center, Teijin Limited, Hino, Tokyo, Japan
    • ,
  • Hiroaki Kaneko, PhD

      Affiliations

    • Department of Tissue Engineering Development, Teijin Technology Innovation Center, Teijin Limited, Hino, Tokyo, Japan
    • ,
  • Yoshihiro Suematsu, MD, PhD

      Affiliations

    • Department of Cardiac Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
    • ,
  • Akihiko Usui, MD, PhD

      Affiliations

    • Nagoya University, Graduate School of Medicine, Department of Cardiothoracic Surgery, Nagoya, Aichi, Japan
    • ,
  • Yuichi Ueda, MD, PhD

      Affiliations

    • Nagoya University, Graduate School of Medicine, Department of Cardiothoracic Surgery, Nagoya, Aichi, Japan

Received 19 June 2008 ,Revised 2 October 2008 ,Accepted 15 November 2008.

References 

  1. Ogus TN, Basaran M, Selimoglu O, Yildirim T, Ogus H, Ozcan H. Long-term results of the left anterior descending coronary artery reconstruction with left internal thoracic artery. Ann Thorac Surg. 2007;83:496–501
  2. Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, et al. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg. 2007;132:373–378
  3. Mack MJ, Osborne JA, Shennib H. Arterial graft patency in coronary artery bypass grafting: what do we really know?. Ann Thorac Surg. 1998;66:1055–1059
  4. Roy-Chaudhury P, Kelly BS, Zhang J, Narayana A, Desai P, Melham M, et al. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif. 2003;21:99–110
  5. Kapadia MR, Popowich DA, Kibbe MR. Modified prosthetic vascular conduits. Circulation. 2008;117:1873–1882
  6. Hosono M, Ueda M, Suehiro S, Suehiro S, Sasaki Y, Shibata T, et al. Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects: an immunohistochemical analysis. J Thorac Cardiovasc Surg. 2000;120:319–328
  7. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331–341
  8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  9. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  10. Bartorelli AL, Trabattoni D, Fabbiocchi F, Montorsi P, de Martini S, Calligaris G, et al. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Interv Cardiol. 2003;16:499–505
  11. Signore PE, Machan LS, Jackson JK, Burt H, Bromley P, Wilson JE, et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol. 2001;12:79–88
  12. Kawatsu S, Oda K, Saiki Y, Tabata Y, Tabayashi K. External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg. 2007;84:560–567
  13. Kelly B, Melhem M, Zhang J, Kasting G, Li J, Krishnamoorthy M, et al. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant. 2006;21:2425–2431
  14. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G, et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. 2004;77:1580–1585
  15. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem. 1993;39:2219–2228
  16. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 1993;30:9–19
  17. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  18. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412–417
  19. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277–2283
  20. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–2170
  21. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–2441
  22. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166–170
  23. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2006;48:286–292
  24. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation. 2005;111:926–931
  25. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 1996;93:2178–2187
  26. Shi Y, O'Brien JE, Ala-Kokko L, Chung W, Mannion JD, Zalewski A. Origin of extracellular matrix synthesis during coronary repair. Circulation. 1997;95:997–1006
  27. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD, Zalewski A. Adventitial remodeling after coronary arterial injury. Circulation. 1996;93:340–348

PII: S0022-5223(08)01971-5

doi: 10.1016/j.jtcvs.2008.11.017

The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 3 , Pages 703-709 , March 2009

Article Tools

* Image Usage & Resolution